Majority Of Indian Firms “Beginners” In Digital Journey
Executive Summary
Many global pharmaceutical companies are well launched on their digital marketing “journeys” to engage with customers, but most of their Indian peers are still only at the beginner’s stage, says a new EY report, warning this could have critical implications in an increasingly competitive market.
You may also be interested in...
As Digital Channels Grow In Importance, AZ, Lilly, GSK Seen As Key Engagers
Digital physician engagement channels appear to be closing in on the traditional face-to-face approach, with China surging ahead on the digital path. The US and China appear more or less in sync when it comes to self-directed web-detailing, while AstraZeneca, Lilly and GSK lead the charts in terms of digital engagement as perceived by healthcare professionals, a new survey shows.
Six Questions For McKinsey's Fox On Pharma's Digital Struggle
Brian Fox, McKinsey & Company's global leader of the marketing and sales group within its pharmaceuticals and medical products practice, refers to pharma's unflattering standing in terms of digital maturity and tells Scrip that drug firms will need to make a "fundamental shift" in their orientation towards patients and physicians to keep pace with other industries well ahead of it in the digital arena.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.